Dror Ben-Asher
Co-Founder & CEO
Claimed by owner RedHill Biopharma
Former names:
Proprietary Drugs for Gastrointestinal and Infectious Diseases
Public on NASDAQ Jan, 2012
RedHill Biopharma
www.prnewswire.com
•
Apr 3, 2023
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
www.prnewswire.com
•
Oct 26, 2022
RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022
www.prnewswire.com
•
May 9, 2022
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
www.benzinga.com
•
Apr 11, 2022
RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants - Redhill Biopharma (NASDAQ:RDHL)
www.eurekalert.org
•
Mar 1, 2022
RedHill announces positive phase 2 study results with oral RHB-107 in non-hospitalized COVID-19
www.prnewswire.com
•
Jan 6, 2022
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates
www.prnewswire.com
•
Nov 18, 2021
RedHill Biopharma Announces Underwritten Public Offering of American Depositary Shares
www.prnewswire.com
•
Sep 14, 2021
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
www.calcalistech.com
•
Feb 28, 2021
Israel's RedHill Biopharma testing oral pill that cures Covid-19 symptoms
www.prnewswire.com
•
Dec 15, 2020
RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model
www.usnews.com
•
Dec 2, 2020
Coronavirus Pandemic Boosting Anti-Virus Research Around the World
www.pharmanewsdaily.com
•
Nov 26, 2020
RedHill Biopharma expands manufacturing capacity of Covid-19 drug candidate opaganib in US - www.PharmaNewsDaily.com
www.globenewswire.com
•
Oct 14, 2020
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
www.calcalistech.com
•
Oct 14, 2020
Israel's Redhill Biopharma signs manufacturing deal for potential Covid-19 treatment
www.globenewswire.com
•
Oct 8, 2020
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
www.globenewswire.com
•
Oct 7, 2020
RedHill Biopharma's Opaganib COVID-19 Study Passes Second Independent Committee Review
www.globenewswire.com
•
Sep 22, 2020
Brazil Approves RedHill Biopharma's Phase 2/3 COVID-19 Study with Opaganib
www.globenewswire.com
•
Sep 8, 2020
RedHill Biopharma's Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
www.globenewswire.com
•
Sep 3, 2020
RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania
www.globenewswire.com
•
Aug 27, 2020
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
www.globenewswire.com
•
Aug 13, 2020
RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
www.globenewswire.com
•
Aug 11, 2020
RedHill Biopharma's Phase 2/3 COVID-19 Study Approved in Mexico
www.globenewswire.com
•
Aug 3, 2020
RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
www.globenewswire.com
•
Jul 31, 2020
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
www.globenewswire.com
•
Jul 31, 2020
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
www.globenewswire.com
•
Jul 30, 2020
RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
www.globenewswire.com
•
Jul 28, 2020
RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
www.globenewswire.com
•
Jul 22, 2020
RedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
www.globenewswire.com
•
Jul 16, 2020
RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia
www.globenewswire.com
•
Jun 29, 2020
RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK
www.globenewswire.com
•
Jun 24, 2020
Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill's Opaganib Compared to Matched Case-Control Group
www.globenewswire.com
•
Jun 18, 2020
RedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK
www.globenewswire.com
•
Jun 10, 2020
RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib
www.globenewswire.com
•
Jun 8, 2020
RedHill Biopharma to Provide Update on its COVID-19 and other Development Programs at MedInvest Virtual Infectious Diseases and Immunology Conference
www.globenewswire.com
•
May 8, 2020
RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
www.globenewswire.com
•
May 5, 2020
RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
www.globenewswire.com
•
Apr 20, 2020
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
www.globenewswire.com
•
Apr 13, 2020
RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel
www.timesofisrael.com
•
Apr 7, 2020
Israel's Redhill Biopharma gets green light for experimental COVID-19 treatment
www.israel21c.org
•
Mar 15, 2020
Israeli pharma company launches drug for H. pylori in US market
www.globenewswire.com
•
Mar 11, 2020
RedHill Biopharma Provides Update on Opaganib (Yeliva®)
www.globenewswire.com
•
Feb 25, 2020
RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners
en.globes.co.il
•
Feb 25, 2020
RedHill buys AstraZeneca constipation drug rights
www.globenewswire.com
•
Jan 27, 2020
RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch
www.globenewswire.com
•
Jan 21, 2020
RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®;Discontinuing Promotion of Legacy Products
www.globenewswire.com
•
Jan 2, 2020
RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106
www.globenewswire.com
•
Dec 17, 2019
RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers' Diarrhea
www.globenewswire.com
•
Nov 15, 2019
Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange
www.globenewswire.com
•
Nov 12, 2019
RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA
www.calcalistech.com
•
Nov 5, 2019
RedHill Receives FDA Approval for H. Pylori Gastric Drug
www.globenewswire.com
•
Oct 18, 2019
RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers' Diarrhea Drug AEMCOLO
www.globenewswire.com
•
Oct 11, 2019
RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn's Disease
www.globenewswire.com
•
Aug 21, 2019
RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn's Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting
www.globenewswire.com
•
Jul 3, 2019
RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®
www.globenewswire.com
•
Jun 10, 2019
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn's Disease and RHB-204 for NTM Infections
www.globenewswire.com
•
May 28, 2019
RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer
www.globenewswire.com
•
May 21, 2019
RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch
www.globenewswire.com
•
May 7, 2019
RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
www.globenewswire.com
•
Mar 4, 2019
RedHill Biopharma Announces New European and Japanese Patents for Talicia®
globenewswire.com
•
Jan 17, 2019
RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection
en.globes.co.il
•
Dec 9, 2018
RedHill Biopharma raises $20m on Nasdaq
www.timesofisrael.com
•
Dec 3, 2018
Israel's RedHill says drug shown effective in eradicating gut infection
www.timesofisrael.com
•
Jul 30, 2018
RedHill's drug for Crohn's disease shows positive results - study
www.calcalistech.com
•
Jul 24, 2018
Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq
seekingalpha.com
•
Nov 17, 2017
RedHill Biopharma: When Good News Means Nothing (NASDAQ:RDHL)
globenewswire.com
•
Nov 13, 2017
RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares
www.marketwired.com
•
Apr 10, 2017
http://www.marketwired.com/press-release/intelgenx-redhill-biopharma-announce-marketing-approval-rizaportr-migraines-luxembourg-otcqx-igxt-2209596.htm
www.globes.co.il
•
Dec 22, 2016
RedHill BioPharma raises $38m in Nasdaq offering
globenewswire.com
•
Jul 22, 2016
RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection
www.globes.co.il
•
Jul 19, 2015
RedHill BioPharma raises $40 million on Nasdaq
www.globes.co.il
•
Jun 15, 2015
RedHill Biopharma soars on Phase III trial results
www.globes.co.il
•
Feb 11, 2015
RedHill Biopharma raises $12.5m on Nasdaq
www.globes.co.il
•
Dec 18, 2014
RedHill boosted by University of Minnesota deal
www.globes.co.il
•
Jan 22, 2014
RedHill Biopharma raises $11.7m in private placement
About
RedHill Biopharma is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.
The company's US commercial operations include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the United States.
RedHill's pipeline includes several drug candidates in advanced clinical development stages, addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
The company's US commercial operations include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the United States.
RedHill's pipeline includes several drug candidates in advanced clinical development stages, addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
Primary Sector
Life Sciences & HealthTech
Products
Talicia, Movantik, Aemcolo
Geographic markets
Israel, United States
Funding
Total Funding
$294.2M
Market Cap
$6.05M
Last Funding
$6M
Funding Stage
Total Rounds
11
Investors
6
News
(74)
www.prnewswire.com
•
Apr 3, 2023
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
www.prnewswire.com
•
Oct 26, 2022
RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022
www.prnewswire.com
•
May 9, 2022
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
www.benzinga.com
•
Apr 11, 2022
RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants - Redhill Biopharma (NASDAQ:RDHL)
www.eurekalert.org
•
Mar 1, 2022
RedHill announces positive phase 2 study results with oral RHB-107 in non-hospitalized COVID-19
www.prnewswire.com
•
Jan 6, 2022
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates
www.prnewswire.com
•
Nov 18, 2021
RedHill Biopharma Announces Underwritten Public Offering of American Depositary Shares
www.prnewswire.com
•
Sep 14, 2021
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
www.calcalistech.com
•
Feb 28, 2021
Israel's RedHill Biopharma testing oral pill that cures Covid-19 symptoms
www.prnewswire.com
•
Dec 15, 2020
RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model
www.usnews.com
•
Dec 2, 2020
Coronavirus Pandemic Boosting Anti-Virus Research Around the World
www.pharmanewsdaily.com
•
Nov 26, 2020
RedHill Biopharma expands manufacturing capacity of Covid-19 drug candidate opaganib in US - www.PharmaNewsDaily.com
www.globenewswire.com
•
Oct 14, 2020
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
www.calcalistech.com
•
Oct 14, 2020
Israel's Redhill Biopharma signs manufacturing deal for potential Covid-19 treatment
www.globenewswire.com
•
Oct 8, 2020
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
www.globenewswire.com
•
Oct 7, 2020
RedHill Biopharma's Opaganib COVID-19 Study Passes Second Independent Committee Review
www.globenewswire.com
•
Sep 22, 2020
Brazil Approves RedHill Biopharma's Phase 2/3 COVID-19 Study with Opaganib
www.globenewswire.com
•
Sep 8, 2020
RedHill Biopharma's Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
www.globenewswire.com
•
Sep 3, 2020
RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania
www.globenewswire.com
•
Aug 27, 2020
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
www.globenewswire.com
•
Aug 13, 2020
RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
www.globenewswire.com
•
Aug 11, 2020
RedHill Biopharma's Phase 2/3 COVID-19 Study Approved in Mexico
www.globenewswire.com
•
Aug 3, 2020
RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
www.globenewswire.com
•
Jul 31, 2020
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
www.globenewswire.com
•
Jul 31, 2020
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
www.globenewswire.com
•
Jul 30, 2020
RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
www.globenewswire.com
•
Jul 28, 2020
RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
www.globenewswire.com
•
Jul 22, 2020
RedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
www.globenewswire.com
•
Jul 16, 2020
RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia
www.globenewswire.com
•
Jun 29, 2020
RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK
www.globenewswire.com
•
Jun 24, 2020
Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill's Opaganib Compared to Matched Case-Control Group
www.globenewswire.com
•
Jun 18, 2020
RedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK
www.globenewswire.com
•
Jun 10, 2020
RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib
www.globenewswire.com
•
Jun 8, 2020
RedHill Biopharma to Provide Update on its COVID-19 and other Development Programs at MedInvest Virtual Infectious Diseases and Immunology Conference
www.globenewswire.com
•
May 8, 2020
RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
www.globenewswire.com
•
May 5, 2020
RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
www.globenewswire.com
•
Apr 20, 2020
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
www.globenewswire.com
•
Apr 13, 2020
RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel
www.timesofisrael.com
•
Apr 7, 2020
Israel's Redhill Biopharma gets green light for experimental COVID-19 treatment
www.israel21c.org
•
Mar 15, 2020
Israeli pharma company launches drug for H. pylori in US market
www.globenewswire.com
•
Mar 11, 2020
RedHill Biopharma Provides Update on Opaganib (Yeliva®)
www.globenewswire.com
•
Feb 25, 2020
RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners
en.globes.co.il
•
Feb 25, 2020
RedHill buys AstraZeneca constipation drug rights
www.globenewswire.com
•
Jan 27, 2020
RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch
www.globenewswire.com
•
Jan 21, 2020
RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®;Discontinuing Promotion of Legacy Products
www.globenewswire.com
•
Jan 2, 2020
RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106
www.globenewswire.com
•
Dec 17, 2019
RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers' Diarrhea
www.globenewswire.com
•
Nov 15, 2019
Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange
www.globenewswire.com
•
Nov 12, 2019
RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA
www.calcalistech.com
•
Nov 5, 2019
RedHill Receives FDA Approval for H. Pylori Gastric Drug
www.globenewswire.com
•
Oct 18, 2019
RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers' Diarrhea Drug AEMCOLO
www.globenewswire.com
•
Oct 11, 2019
RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn's Disease
www.globenewswire.com
•
Aug 21, 2019
RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn's Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting
www.globenewswire.com
•
Jul 3, 2019
RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®
www.globenewswire.com
•
Jun 10, 2019
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn's Disease and RHB-204 for NTM Infections
www.globenewswire.com
•
May 28, 2019
RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer
www.globenewswire.com
•
May 21, 2019
RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch
www.globenewswire.com
•
May 7, 2019
RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
www.globenewswire.com
•
Mar 4, 2019
RedHill Biopharma Announces New European and Japanese Patents for Talicia®
globenewswire.com
•
Jan 17, 2019
RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection
en.globes.co.il
•
Dec 9, 2018
RedHill Biopharma raises $20m on Nasdaq
www.timesofisrael.com
•
Dec 3, 2018
Israel's RedHill says drug shown effective in eradicating gut infection
www.timesofisrael.com
•
Jul 30, 2018
RedHill's drug for Crohn's disease shows positive results - study
www.calcalistech.com
•
Jul 24, 2018
Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq
seekingalpha.com
•
Nov 17, 2017
RedHill Biopharma: When Good News Means Nothing (NASDAQ:RDHL)
globenewswire.com
•
Nov 13, 2017
RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares
www.marketwired.com
•
Apr 10, 2017
http://www.marketwired.com/press-release/intelgenx-redhill-biopharma-announce-marketing-approval-rizaportr-migraines-luxembourg-otcqx-igxt-2209596.htm
www.globes.co.il
•
Dec 22, 2016
RedHill BioPharma raises $38m in Nasdaq offering
globenewswire.com
•
Jul 22, 2016
RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection
www.globes.co.il
•
Jul 19, 2015
RedHill BioPharma raises $40 million on Nasdaq
www.globes.co.il
•
Jun 15, 2015
RedHill Biopharma soars on Phase III trial results
www.globes.co.il
•
Feb 11, 2015
RedHill Biopharma raises $12.5m on Nasdaq
www.globes.co.il
•
Dec 18, 2014
RedHill boosted by University of Minnesota deal
www.globes.co.il
•
Jan 22, 2014
RedHill Biopharma raises $11.7m in private placement
The Team
(5)
DB
GG
Guy Goldberg
CBO
MBC
Micha Ben Chorin
CFO
GR
Gilead Raday
COO
AF
Adi Frish
SVP BD & Licensing
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
Undisclosed
Jan 2012
Stock Exchange
NASDAQ
Valuation
Undisclosed
Undisclosed
Public Offering
Undisclosed
Dec 2012
Stock Exchange
TASE
Valuation
Undisclosed
Undisclosed
Public Offering
$12M
Feb 2015
Stock Exchange
NASDAQ
Valuation
Undisclosed
$12M
Public Offering
$40M
Jul 2015
Stock Exchange
NASDAQ
Valuation
Undisclosed
$40M
Public Offering
$38M
Dec 2016
Stock Exchange
NASDAQ
Valuation
Undisclosed
$38M
Public Offering
$20M
Dec 2018
Stock Exchange
NASDAQ
Valuation
Undisclosed
$20M
Delisting
Feb 2020
Stock Exchange
TASE
Private Equity Funding
Post-IPO Equity Funding
$11.7M
Jan 2014
4 Investors
$11.7M
Post-IPO Equity Funding
$36M
Oct 2018
1 Investors
$36M
Debt Financing
$115M
Feb 2020
1 Investors
$115M
Post-IPO Equity Funding
$15.5M
Nov 2021
$15.5M
Post-IPO Equity Funding
$6M
Apr 2023
$6M
Media gallery
(0)Locations
Israel
21 Haarbaa St., 6473921, Tel Aviv, Israel
Offices Abroad
8045 Arco Corporate Drive, Raleigh, NC, USA
Locations
Israel
21 Haarbaa St., 6473921, Tel Aviv, Israel
Offices Abroad
8045 Arco Corporate Drive, Raleigh, NC, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,